Status:
COMPLETED
A Promotion and Implementation Project of HIV Pre-Exposure Prophylaxis Among High Risk Population
Lead Sponsor:
University of Chicago
Collaborating Sponsors:
Gilead Sciences
Guangzhou 8th People's Hospital
Conditions:
HIV Preexposure Prophylaxis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This study aims to use a social media mini-application-enabled intervention to successfully promote the initiation and persistence of pre-exposure prophylaxis (PrEP) among at-risk people 18 years and ...
Detailed Description
The China National Medical Products Administration (NMPA) recently approved TDF/FTC (Truvada) for PrEP making it the first HIV prevention medicine available in China. While this is a significant step ...
Eligibility Criteria
Inclusion
- Age 18+
- Engaged in at-risk sex. At risk sex is defined as sex with \>1 partner in the past 90 days, inconsistent condom use with vaginal or anal sex, ongoing sexual relationship with an HIV-positive partner, participation in commercial sex work, or any bacterial STI diagnosed or reported in the past 6 months.
Exclusion
- History renal dysfunction
- Chronic hepatitis B (HBV) infection
- HIV infection
- Indication for HIV post-exposure prophylaxis
- Signs and symptoms consistent with acute HIV infection
- Under the age range of 18
Key Trial Info
Start Date :
September 24 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 30 2024
Estimated Enrollment :
1200 Patients enrolled
Trial Details
Trial ID
NCT04754139
Start Date
September 24 2021
End Date
September 30 2024
Last Update
October 3 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Guangzhou Eighth People's Hospital
Guangzhou, China
2
Zhongnan Hospital of Wuhan University
Wuhan, China